A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors
Solid Tumor
DRUG: YH003|DRUG: YH001|DRUG: Pembrolizumab
Adverse events (AEs), The safety will be assessed by monitoring the adverse events (AE) per NCI CTCAE v5.0, up to 1 year after the last dosing|Maximum tolerated dose (MTD) and/or Recommended phase 2 dose (RP2D), The MTD and/or RP2D will be determined based on the data of safety and tolerability, up to 1 year after the last dosing
A Multicenter, Open-Label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors